Welcome to our dedicated page for Vystar news (Ticker: VYST), a resource for investors and traders seeking the latest updates and insights on Vystar stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vystar's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vystar's position in the market.
Vystar Corporation (OTCQB: VYST) has appointed Byron Novosad, DDS, to its Board of Directors, replacing retired member Keith Osborn, MD. CEO Steve Rotman expressed gratitude for Dr. Osborn's service and welcomed Dr. Novosad, noting his extensive experience and commitment as an investor and advisor. Dr. Novosad aims to enhance shareholder value through strategic execution and communication of Vystar's vision, particularly in health-related product lines such as RxAir UV purifiers and Vytex deproteinized latex. His background and insights are expected to positively influence Vystar's future growth.
Vystar Corporation (OTCQB: VYST) has partnered with 5W Public Relations to enhance media presence and brand recognition for its RxAir UV light air purification products. This collaboration aims to address growing consumer concerns about airborne disease transmission due to the COVID-19 pandemic. 5WPR will implement a targeted media relations program and influencer campaigns to promote RxAir's effectiveness in eliminating 99.9% of airborne viruses, including various strains of coronaviruses. RxAir products are FDA cleared as Class II Medical Devices, designed initially for healthcare environments.
Vystar Corporation (OTCQB: VYST) has partnered with Corrie MacColl Limited for global market development and distribution of Vytex deproteinized latex. The three-year agreement allows Corrie MacColl to utilize its extensive supply chain and sustainability practices to produce Vytex from its eco-friendly Cameroon plantations. This partnership aims to enhance Vytex's global reach, expected to add shareholder value without significant costs, and positions Vystar to enter new markets in sustainable applications for products like tires and medical devices.
Vystar Corporation (OTCQB: VYST) reports significant advancements amid COVID-19 challenges, enhancing its supply chain and product offerings, particularly through its RxAir UV air purifiers, which have seen increased demand. The company produced over 10,000 units of the RxAir 400 and aims to manufacture the Rx3000 by Q1 2021. Additionally, Rotmans Furniture expects a surge in sales due to a clearance sale and renovation plans. The company is pursuing strategic partnerships to support growth while minimizing debt. Vystar remains committed to spinning off RxAir as a public entity, enhancing shareholder value.
Vystar Corporation (OTCQB: VYST) announces the assembly and testing of its Rx3000® UV-C Light/HEPA Air Purifier prototypes, a Class II medical device designed to inactivate 99.9% of airborne pathogens. The units are being developed to meet rising demand in various sectors due to COVID-19. Strategic Link is facilitating the manufacturing process amidst supply chain challenges. Pre-orders for the Rx3000 will begin on October 18, 2020, highlighting Vystar's commitment to enhancing air quality in healthcare settings and beyond.
Vystar Corporation (OTCQB: VYST) announces that Eagle Hill School is the first school to implement the RxAir 400 UV-C Light Air Purifier Systems across its campus. These FDA-certified devices effectively inactivate 99.9% of airborne viruses and bacteria, enhancing safety for in-person education. The school installed 95 units, ensuring up to six air changes per hour in large spaces. Vystar is offering discounted bulk orders to educational institutions, aiming to promote healthier learning environments. The partnership will showcase the effectiveness of RxAir in reducing airborne pathogen risks.
Vystar Corporation (OTCQB: VYST) has successfully paid off over $2 million in debt since July 1, 2020, including multiple notes and lines of credit. This consolidation is timely as Vystar enters the crucial fourth quarter, with its RxAir UV-C Light air purifier line and Rotmans home furnishings. Notably, the company benefited from $1.4 million in government PPP funding during the COVID-19 shutdown, facilitating debt repayment and operational growth. Vystar's CEO emphasized the solid business position and upcoming production restarts for RxAir units, alongside new product developments.
